Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy (2024)
Sequence: WEARLARALARALARHLARALARALRACEA
| Experiment Id | EXP002462 |
|---|---|
| Paper | Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy |
| Peptide | RALA |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Set by N/P ratio (N/P=10 used for subsequent studies); exact mass/µM not reported |
| Rna Concentration | 2.5 µg mRNA complex added to BMDCs for 24 h (50 µL complex to cells) |
| Mixing Ratio | N/P = 10 |
| Formulation Format | Ex vivo DC loading (neoantigen-mRNA/RALA) → DC vaccine |
| Formulation Components | RALA + neoantigen mRNA polyplex; bone-marrow-derived DCs; GM-CSF/IL-4 culture; LPS maturation |
| Size Nm | |
| Zeta Mv | 26.20 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | Primary bone-marrow-derived DCs (C57BL/6) used as vaccine cells |
| Animal Model | C57BL/6 male mice with MC38 subcutaneous tumors |
| Administration Route | Subcutaneous injections of DC vaccine on days 7, 14, 21 post tumor inoculation (plus group with adoptive TIL) |
| Output Type | Antitumor efficacy (tumor volume/weight); immune readouts (CD8+ IFN-γ+ infiltration, cytokines) |
| Output Value | Tumor volume reduced vs PBS: ~606±43 mm³ (NeoAg-mRNA/DC) and ~391±74 mm³ (NeoAg-mRNA/DC + TIL) vs ~1433±65 mm³ (PBS) |
| Output Units | |
| Output Notes | Significant tumor growth inhibition; increased CD4+IFN-γ+ and CD8+IFN-γ+ TILs; increased serum IL-6, IL-12p70, TNF-α, IFN-γ |
| Toxicity Notes | No significant body-weight loss; no reported toxic/side effects in treated groups |
| Curation Notes |